

Dirk Beher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1439749/publications.pdf>

Version: 2024-02-01

13
papers

727
citations

840585

11
h-index

1199470

12
g-index

13
all docs

13
docs citations

13
times ranked

902
citing authors

#	ARTICLE	IF	CITATIONS
1	O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and $\hat{1}\pm$ -Synuclein Proteinopathies. ACS Chemical Neuroscience, 2022, 13, 1296-1314.	1.7	24
2	O1â€12â€05: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE Oâ€GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES. Alzheimer's and Dementia, 2018, 14, P251.	0.4	17
3	O3â€04â€04: Pharmacological intervention with the novel oâ€glcnacase inhibitor ASNâ€561 reduces pathological tau in transgenic mice. Alzheimer's and Dementia, 2015, 11, P227.	0.4	11
4	O1-10-01: PRECLINICAL PROFILES OF DRUG CANDIDATES PROMOTING O-LINKED GLYCOSYLATION OF TAU FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND TAUOPATHIES. , 2014, 10, P148-P149.		2
5	Substrate determinants in the C99 juxtamembrane domains differentially affect $\hat{1}^3$ â€secretase cleavage specificity and modulator pharmacology. Journal of Neurochemistry, 2013, 125, 610-619.	2.1	23
6	Generation and characterization of a rabbit monoclonal antibody siteâ€specific for tau Oâ€GlcNAcylated at serine 400. FEBS Letters, 2013, 587, 3722-3728.	1.3	28
7	Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2012, 4, 9.	3.0	137
8	Protease inhibitors as potential disease-modifying therapeutics for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2005, 14, 1385-1409.	1.9	53
9	Functional Overexpression of $\hat{1}^3$ -Secretase Reveals Protease-independent Trafficking Functions and a Critical Role of Lipids for Protease Activity. Journal of Biological Chemistry, 2005, 280, 12523-12535.	1.6	35
10	Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target $\hat{1}^3$ -Secretase at a Novel Site. Journal of Biological Chemistry, 2004, 279, 43419-43426.	1.6	171
11	In Vitro Characterization of the Presenilin-Dependent $\hat{1}^3$ -Secretase Complex Using a Novel Affinity Ligand. Biochemistry, 2003, 42, 8133-8142.	1.2	79
12	The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1365-1370.	3.3	71
13	Generation of C-terminally truncated amyloid- $\hat{1}^2$ peptides is dependent on $\hat{1}^3$ -secretase activity. Journal of Neurochemistry, 2002, 82, 563-575.	2.1	76